STOCKWATCH

Alivus Life Sciences Ltd. Receives VAI Status from USFDA for API Manufacturing Facility

Alivus Life Sciences Ltd. has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA) for their Active Pharmaceutical Ingredient (API) manufacturing facility at Plot No. 3102 to 3109, 3103, GIDC Industrial Estate, Ankleshwar, Gujarat. The inspection was conducted by the USFDA from 27th January, 2025 to 31st January, 2025.

• Alivus Life Sciences Ltd. has been issued an Establishment Inspection Report (EIR) by the USFDA.
• The USFDA has indicated a Voluntary Action Indicated (VAI) status for the API manufacturing facility.
• The inspection by the USFDA took place from 27th January, 2025 to 31st January, 2025.
• The manufacturing facility is located at Plot No. 3102 to 3109, 3103, GIDC Industrial Estate, Ankleshwar, Gujarat.